Navigation Links
Simcere Pharmaceutical Group Files Annual Report on Form 20-F
Date:6/30/2010

NANJING, China, June 30 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of branded generic and innovative pharmaceuticals in China, today announced the filing of its annual report on Form 20-F for the year ended December 31, 2009 with the Securities and Exchange Commission on June 30, 2010. The annual report can be accessed on the Company's website at http://www.simcere.com under the investor relations section. The Company will provide a hard copy of its audited financial statements for the year ended December 31, 2009, free of charge, to its shareholders and ADS holders upon request.

The Company previously announced that its preliminary unaudited 2009 financial results were subject to the completion of the impairment review of goodwill and intangible assets and the purchase price allocation with respect to the Company's acquisition of Jiangsu Yanshen Biological Technology Stock Co., Ltd. ("Jiangsu Yanshen"). Management has completed the goodwill impairment analysis and the purchase price allocation and as a result has revised the Company's previously reported preliminary unaudited 2009 financial results. The revision has resulted in a decrease in net income from RMB155.9 million to RMB28.9 million (US$4.2 million), a decrease in net income attributable to the non-controlling interest from RMB36.4 million to RMB2.4 million (US$0.4 million), and a decrease in net income attributable to Simcere from RM119.5 million to RMB26.4 million (US$3.9 million). After the revision, the Company's basic and diluted earnings per American Depository Share (ADS) for the year ended December 31, 2009 were RMB0.46 (US$0.07) and RMB0.45 (US$0.07), respectively. One ADS represents two ordinary shares of the Company.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE:SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells antibiotics, anti-cancer medication, stroke management medication and biopharmaceutical drugs such as vaccines. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, orthopaedics and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .

    Investor and Media Contacts:
     Email: ir@simcere.com

    In Nanjing:
     Frank Zhao
     Chief Financial Officer
     Simcere Pharmaceutical Group
     Tel: +86-25-8556-6666 ext 8818

    In the United States:
     Kate Tellier
     Brunswick Group
     Tel: +1-212-333-3810

    In Beijing:
     Ruirui Jiang
     Brunswick Group
     Tel: +86-10-6566-2256

    In Hong Kong:
     Joseph Lo Chi-Lun
     Brunswick Group
     Tel: +852-3512-5000


'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results
2. Simceres Diosmectite API Passes EU-GMP Inspection
3. Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study
4. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Tuesday, March 16, 2010
5. Simcere Receives SFDA Approval to Manufacture and Sell Zanamivir in China
6. Simcere Pharmaceutical Group Provides Update on Jiangsu Yanshen
7. Simcere Pharmaceutical Group Announces Jiangsu Yanshens Voluntary Suspension of Production
8. Simcere Pharmaceutical Group to Acquire Additional Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd.
9. Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals
10. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
11. Renhuang to Launch New Bio-pharmaceutical Product - Ginseng and Deer Antler Extract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced ... Act of 1976, as amended ("HSR"), with respect to ... CPXX ) expired effective June 24, 2016, ... previously announced on May 31, 2016, Jazz Pharmaceuticals and ... Jazz Pharmaceuticals has commenced a tender offer for all ...
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
Breaking Medicine Technology:
(Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
Breaking Medicine News(10 mins):